Skip to main content
Erschienen in: Drugs & Aging 6/2009

01.06.2009 | Original Research Article

Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US

An Analysis of National Survey Data

verfasst von: Pravin Kamble, Hua Chen, Jeffrey T. Sherer, Dr Rajender R. Aparasu

Erschienen in: Drugs & Aging | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Atypical antipsychotic agents are increasingly being used for the treatment of behavioural and psychological symptoms of dementia. However, recent data suggest that the risk of adverse effects may offset the benefits of atypical agents in patients with dementia.

Objectives

To examine utilization of antipsychotic medications and the factors associated with use of atypical antipsychotics among elderly nursing home residents with dementia.

Methods

The study involved the analysis of prescription and resident files of a nationally representative sample of residents from the 2004 National Nursing Home Survey (NNHS). The study sample included an unweighted sample of 6103 elderly nursing home residents aged ≥65 years with dementia. The analysis focused on the use of six atypical antipsychotic agents and 11 typical agents. Descriptive weighted analysis was performed to examine the antipsychotic prevalence patterns in elderly nursing home residents with dementia. Multiple logistic regression analysis within the conceptual framework of Andersen’s Behavioural Model was used to examine the predisposing, enabling and need characteristics associated with use of atypical antipsychotics.

Results

According to the 2004 NNHS, the overall prevalence of dementia among elderly nursing home residents was 52.58%. Most of the elderly with dementia were female (77%), aged ≥85 years (56%), non-Hispanic (97%) and White (88%). Antipsychotic medications were taken by 32.88% of elderly patients with dementia. More elderly residents received atypical agents (31.63%) than typical agents (1.75%). Among the predisposing characteristics, the odds of receiving atypical antipsychotics were lower for females than males. The enabling factor facility bed capacity was significantly associated with use of atypical antipsychotics. Among the need characteristics, the likelihood of receiving atypical antipsychotic agents increased with dependence in decision-making ability, indicators of depressed mood and behavioural symptoms. The likelihood of receiving atypical antipsychotic agents decreased with increasing dependence for out-of-bed mobility and increased total activities of daily living. The odds of receiving atypical antipsychotic treatment increased with the diagnosis of schizophrenia, bipolar mania and anxiety among dementia patients.

Conclusion

Nearly one-third of elderly nursing home residents with dementia received antipsychotic medications, mainly atypical agents. Predisposing, enabling and need factors influenced the use of atypical agents in dementia patients. These findings suggest a need to optimize use of atypical antipsychotics in elderly dementia patients in nursing homes in the light of recent efficacy and safety data.
Literatur
1.
Zurück zum Zitat Agency of Healthcare Research and Quality. Efficacy and comparative effectiveness of off-label use of atypical anti-psychotics [publication no. 07-EHC003-EF]. Rockville (MD): Agency of Healthcare Research and Quality, 2007 Agency of Healthcare Research and Quality. Efficacy and comparative effectiveness of off-label use of atypical anti-psychotics [publication no. 07-EHC003-EF]. Rockville (MD): Agency of Healthcare Research and Quality, 2007
2.
Zurück zum Zitat Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRef Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRef
3.
Zurück zum Zitat Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Gerontologist 2000; 40: 663–72PubMedCrossRef Magaziner J, German P, Zimmerman SI, et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: diagnosis by expert panel. Gerontologist 2000; 40: 663–72PubMedCrossRef
4.
Zurück zum Zitat Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study. J Clin Epidemiol 2002; 55:462–8PubMedCrossRef Eaker ED, Vierkant RA, Mickel SF. Predictors of nursing home admission and/or death in incident Alzheimer’s disease and other dementia cases compared to controls: a population-based study. J Clin Epidemiol 2002; 55:462–8PubMedCrossRef
5.
Zurück zum Zitat Margallo-Lana M, Swann A, O’Brian J, et al. Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int JGeriatr Psychiatry 2001; 16: 39–44CrossRef Margallo-Lana M, Swann A, O’Brian J, et al. Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia sufferers living in care environments. Int JGeriatr Psychiatry 2001; 16: 39–44CrossRef
6.
Zurück zum Zitat Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1991; 3: 371–6PubMed Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 1991; 3: 371–6PubMed
7.
8.
Zurück zum Zitat Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMed Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38: 553–63PubMed
9.
Zurück zum Zitat Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59(10): 550–61PubMedCrossRef Lanctot KL, Best TS, Mittman N, et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J Clin Psychiatry 1998; 59(10): 550–61PubMedCrossRef
10.
Zurück zum Zitat Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61Suppl. 8: 5–11PubMed Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61Suppl. 8: 5–11PubMed
11.
Zurück zum Zitat Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRef Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRef
12.
Zurück zum Zitat Jeste DV, Lacro JP, Bailey A, et al. Incidence of tardive dyskinesia with risperidone versus haloperidol in older patients. J Am Geriatr Society 1999; 47: 716–9 Jeste DV, Lacro JP, Bailey A, et al. Incidence of tardive dyskinesia with risperidone versus haloperidol in older patients. J Am Geriatr Society 1999; 47: 716–9
13.
Zurück zum Zitat Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000 Jul; 157(7): 1150–5PubMedCrossRef Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000 Jul; 157(7): 1150–5PubMedCrossRef
14.
Zurück zum Zitat Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972–82PubMedCrossRef Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry 2006; 67(6): 972–82PubMedCrossRef
15.
Zurück zum Zitat Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35(3): 187–91PubMedCrossRef Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35(3): 187–91PubMedCrossRef
16.
Zurück zum Zitat Verma SD, Davidoff DA, Kambhampati KK. Management of the agitated elderly patients in the nursing homes: the role of the atypical antipsychotics. J Clin Psychiatry 1998; 59(19): 50–5PubMed Verma SD, Davidoff DA, Kambhampati KK. Management of the agitated elderly patients in the nursing homes: the role of the atypical antipsychotics. J Clin Psychiatry 1998; 59(19): 50–5PubMed
17.
Zurück zum Zitat Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61(14): 49–51PubMed Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry 2000; 61(14): 49–51PubMed
18.
Zurück zum Zitat Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75–8PubMedCrossRef Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75–8PubMedCrossRef
21.
Zurück zum Zitat Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRef Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRef
22.
Zurück zum Zitat Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; CD003476 Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006; CD003476
23.
Zurück zum Zitat Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43PubMedCrossRef Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934–43PubMedCrossRef
24.
Zurück zum Zitat Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res 2006; 55(4): 252–8PubMedCrossRef Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res 2006; 55(4): 252–8PubMedCrossRef
25.
Zurück zum Zitat Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community dwelling and institutionalized Medicare beneficiaries. Am Geriatric Soc 2007; 55: 1508–16CrossRef Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community dwelling and institutionalized Medicare beneficiaries. Am Geriatric Soc 2007; 55: 1508–16CrossRef
27.
Zurück zum Zitat Koch H, Cambell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 1982; 2: 1–90 Koch H, Cambell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 1982; 2: 1–90
29.
Zurück zum Zitat Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973; 51: 95–124PubMedCrossRef Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc 1973; 51: 95–124PubMedCrossRef
30.
Zurück zum Zitat Gray SL, Hanlon JT, Fillenbaum GG, et al. Predictors of nutritional supplement use by the elderly. Pharma-cotherapy 1996; 16(4): 715–20 Gray SL, Hanlon JT, Fillenbaum GG, et al. Predictors of nutritional supplement use by the elderly. Pharma-cotherapy 1996; 16(4): 715–20
31.
Zurück zum Zitat Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003; 51: 671–7PubMedCrossRef Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003; 51: 671–7PubMedCrossRef
32.
Zurück zum Zitat Liperoti R, Mor V, Lapane K, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106–12PubMedCrossRef Liperoti R, Mor V, Lapane K, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64(9): 1106–12PubMedCrossRef
33.
Zurück zum Zitat Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66(9): 1090–6PubMedCrossRef Liperoti R, Gambassi G, Lapane KL, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005; 66(9): 1090–6PubMedCrossRef
34.
Zurück zum Zitat Sorensen L, Foldspang A, Gulmann N, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2000; 16(2): 147–54CrossRef Sorensen L, Foldspang A, Gulmann N, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2000; 16(2): 147–54CrossRef
35.
Zurück zum Zitat Hien L, Cumming R, Cameron I, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53(8): 1290–5CrossRef Hien L, Cumming R, Cameron I, et al. Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc 2005; 53(8): 1290–5CrossRef
36.
Zurück zum Zitat Frenchman BI. Atypical antipsychotics for nursing home patients a retrospective chart review. Drugs Aging 2005; 22(3): 257–64PubMedCrossRef Frenchman BI. Atypical antipsychotics for nursing home patients a retrospective chart review. Drugs Aging 2005; 22(3): 257–64PubMedCrossRef
37.
Zurück zum Zitat Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167: 676–83PubMedCrossRef Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167: 676–83PubMedCrossRef
38.
Zurück zum Zitat Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003; 18: 511–9PubMedCrossRef Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003; 18: 511–9PubMedCrossRef
39.
Zurück zum Zitat Sclar DA, Robison LM, Gavrun C, et al. Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor? Gen Hosp Psychiatry 2008; 30: 73–6PubMedCrossRef Sclar DA, Robison LM, Gavrun C, et al. Hospital length of stay for children and adolescents diagnosed with depression: is primary payer an influencing factor? Gen Hosp Psychiatry 2008; 30: 73–6PubMedCrossRef
40.
Zurück zum Zitat McLaughlin T, Geissler EC, Wan GJ. Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy 2003; 23(10): 1251–6PubMedCrossRef McLaughlin T, Geissler EC, Wan GJ. Comorbidities and associated treatment charges in patients with anxiety disorders. Pharmacotherapy 2003; 23(10): 1251–6PubMedCrossRef
41.
Zurück zum Zitat Tour TL, Brandt NJ, Limcangco MR, et al. Impact of second-generation antipsychotics on the use of anti-parkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother 2006; 4(1): 25–35CrossRef Tour TL, Brandt NJ, Limcangco MR, et al. Impact of second-generation antipsychotics on the use of anti-parkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother 2006; 4(1): 25–35CrossRef
43.
Zurück zum Zitat Buchanan RJ, Wang S, Ju H, et al. Analyses of gender differences in profiles of nursing home residents with Alzheimer’s disease. Gend Med 2001; 1: 48–59CrossRef Buchanan RJ, Wang S, Ju H, et al. Analyses of gender differences in profiles of nursing home residents with Alzheimer’s disease. Gend Med 2001; 1: 48–59CrossRef
44.
Zurück zum Zitat Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000; 38(12): 1164–73PubMedCrossRef Hughes CM, Lapane KL, Mor V. Influence of facility characteristics on use of antipsychotic medications in nursing homes. Med Care 2000; 38(12): 1164–73PubMedCrossRef
Metadaten
Titel
Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US
An Analysis of National Survey Data
verfasst von
Pravin Kamble
Hua Chen
Jeffrey T. Sherer
Dr Rajender R. Aparasu
Publikationsdatum
01.06.2009
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 6/2009
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200926060-00005

Weitere Artikel der Ausgabe 6/2009

Drugs & Aging 6/2009 Zur Ausgabe

Original Research Article

“I Just Take What I Am Given”

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.